CMG Pharmaceutical Co., Ltd. (KOSDAQ:058820)
South Korea flag South Korea · Delayed Price · Currency is KRW
569.00
+3.00 (0.53%)
Sep 18, 2026, 3:30 PM KST

CMG Pharmaceutical Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2019
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '19
Revenue
115,709105,22999,10093,90782,19758,623
Revenue Growth
22.15%6.19%5.53%14.24%40.21%17.56%
Gross Profit
64,47760,87745,64343,59240,75228,885
Operating Income
-3,629-3,6921,0203,0372,9812,604
Net Income
4,640-10,0772,6956,455-388.143,051
Earnings Per Share
31.39-69.875.0046.00-3.0025.00
EPS Growth
---89.13%---55.12%

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2019
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '19
Cash & Investments
17,80326,50276,79468,82777,813119,574
Total Debt
68,70172,00879,96526,1196,713286.39
Net Cash (Debt)
-50,898-45,506-3,17142,70871,100119,288
Net Cash Growth
----39.93%-40.40%119.02%
Net Cash Per Share
-344.36-315.51-5.88307.49511.91981.40

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2019
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '19
Operating Cash Flow
-10,723-11,020290.093,9384,9382,823
Capital Expenditures
-38,729-29,630-28,098-12,384-8,382-8,176
Free Cash Flow
-49,451-40,650-27,808-8,446-3,444-5,352
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2019
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '19
Gross Margin
55.72%57.85%46.06%46.42%49.58%49.27%
Operating Margin
-3.14%-3.51%1.03%3.23%3.63%4.44%
Pretax Margin
4.02%-11.25%2.91%7.17%-1.53%6.54%
Profit Margin
4.01%-9.58%2.72%6.87%-0.47%5.21%
FCF Margin
-42.74%-38.63%-28.06%-8.99%-4.19%-9.13%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2019
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '19
PE Ratio
18.12-91.1351.85-193.46
PS Ratio
0.732.612.483.563.6310.07